Analysts believe the Eucrisa’s advantages will help it be taken up quickly in the US, though Pfizer may well face some concerted opposition from payers on its price.

Pfizer's rival treatment Eucrisa was approved before Christmas – a significant achievement as the drug was the first non-steroidal therapy for the skin condition in more than 15 years.